Developing Nonviral Gene Therapy for Hemophilia A
CGTLive | January 9, 2023
Takeda’s Poseida Partnership Starts to Pay Off with Promising Hemophilia A Gene Therapy Data
Fierce Biotech | December 14, 2022
The Top Line
Fierce Biotech | November 11, 2022
Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic Therapies
CGT Live | October 14, 2022
Allogeneic Cell Therapy Results: Delving A Little Deeper
Cell & Gene | October 3, 2022
CRISPR-Cas9 Alternatives: Cutting through the Boundaries of Gene Editing
Genetic Engineering & Biotechnology News | August 24, 2022
CAR-T Cell Therapies for Hematologic Malignancies the Focus of New Poseida, Roche Collaboration
CGT Live | August 8, 2022
Roche Dives Deeper into Off-The-Shelf Cell Therapies in Poseida Partnership
Gene Online | August 4, 2022
Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner
Endpoints News | August 3, 2022
Novel Cell and Gene Therapies
Mark Gergen, CEO, Poseida Therapeutics, Inc.
Biotech 2050 Podcast | July 13, 2022
Moving on from AAV with Poseida Therapeutics’ CEO, Mark Gergen
Cell & Gene: The Podcast | June 22, 2022
Spotlight on Poseida’s CAR-T Strategy
Celltelligence | June 22, 2022
Providing new hope for rare disease using non-viral gene therapy
Drug Target Review | June 20, 2022
The “Renaissance” Approach To Cell & Gene Therapy Manufacturing
Cell & Gene Collaborative | June 13, 2022
Targeting Solid Tumors with Cell Therapies
Cell & Gene | March 29, 2022
Building the Next-Generation of Cell and Gene Therapies
The Bio Report Podcast | March 23, 2022
Interview with Poseida CEO Mark Gergen
Tacos and Tech Podcast | March 8, 2022
Poseida taps former Novartis VP as president of gene therapy
Fierce Biotech | February 22, 2022
Memory T Cell CAR T Therapy Showcases Anti-Tumor Activity
in Resistant Prostate Cancer
CGT Live | February 17, 2022